[Fever and infectious complications in patient with lung cancer].
The respiratory infections are very frequent during lung cancer. Their diagnosis is often difficult because of the various etiologies (cancer, chemotherapy, radiotherapy) and this complexity can make discuss a preliminary bronchial exploration before any therapeutics. When it is about a located infection, germs in cause are often the same that in the community respiratory infections, in particular bacilli Gram negative, and it is thus logical to treat by the penicillin A. In front of an interstitial syndrome, it is necessary to evoke the opportunist infections, which are increasing in patients with cancer because of the multimodality therapeutic and the elongation of the survival. The neutropenic patient must be distinguished because of its specificities. The pulmonary infections lead to an important mortality. According to the patient (advanced age, underlying chronic obstructive pulmonary disease [COPD]) and to the treatment (chemotherapy, pneumonectomy), prevention must be discussed as the pneumococcal and Haemophilus influenzae vaccination.
Merad-Taoufik
M
M
Service des Urgences, Institut Gustave-Roussy, 39 Rue Camille-Desmoulins, 94805 Villejuif Cedex, France. mmerad@igr.fr
Antoun
S
S
Ruffié
P
P
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D005335:Fever of Unknown Origin / Q000209:etiology* / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D009503:Neutropenia / Q000150:complications; D009894:Opportunistic Infections / Q000209:etiology* / Q000628:therapy; D010166:Palliative Care; D018410:Pneumonia, Bacterial / Q000209:etiology* / Q000628:therapy; D015996:Survival Rate
D000900:Anti-Bacterial Agents